Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1999 Apr;64(4):1002–1014. doi: 10.1086/302333

Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.

C E Jackson 1, R E Fischer 1, A P Hsu 1, S M Anderson 1, Y Choi 1, J Wang 1, J K Dale 1, T A Fleisher 1, L A Middelton 1, M C Sneller 1, M J Lenardo 1, S E Straus 1, J M Puck 1
PMCID: PMC1377824  PMID: 10090885

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of lymphocyte homeostasis and immunological tolerance. Most patients have a heterozygous mutation in the APT1 gene, which encodes Fas (CD95, APO-1), mediator of an apoptotic pathway crucial to lymphocyte homeostasis. Of 17 unique APT1 mutations in unrelated ALPS probands, 12 (71%) occurred in exons 7-9, which encode the intracellular portion of Fas. In vitro, activated lymphocytes from all 17 patients showed apoptotic defects when exposed to an anti-Fas agonist monoclonal antibody. Similar defects were found in a Fas-negative cell line transfected with cDNAs bearing each of the mutations. In cotransfection experiments, Fas constructs with either intra- or extracellular mutations caused dominant inhibition of apoptosis mediated by wild-type Fas. Two missense Fas variants, not restricted to patients with ALPS, were identified. Variant A(-1)T at the Fas signal-sequence cleavage site, which mediates apoptosis less well than wild-type Fas and is partially inhibitory, was present in 13% of African American alleles. Among the ALPS-associated Fas mutants, dominant inhibition of apoptosis was much more pronounced in mutants affecting the intracellular, versus extracellular, portion of the Fas receptor. Mutations causing disruption of the intracellular Fas death domain also showed a higher penetrance of ALPS phenotype features in mutation-bearing relatives. Significant ALPS-related morbidity occurred in 44% of relatives with intracellular mutations, versus 0% of relatives with extracellular mutations. Thus, the location of mutations within APT1 strongly influences the development and the severity of ALPS.

Full Text

The Full Text of this article is available as a PDF (348.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold A., Horst S. A., Gardella T. J., Baba H., Levine M. A., Kronenberg H. M. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest. 1990 Oct;86(4):1084–1087. doi: 10.1172/JCI114811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Behrmann I., Walczak H., Krammer P. H. Structure of the human APO-1 gene. Eur J Immunol. 1994 Dec;24(12):3057–3062. doi: 10.1002/eji.1830241221. [DOI] [PubMed] [Google Scholar]
  3. Beltinger C., Kurz E., Böhler T., Schrappe M., Ludwig W. D., Debatin K. M. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood. 1998 May 15;91(10):3943–3951. [PubMed] [Google Scholar]
  4. Bettinardi A., Brugnoni D., Quiròs-Roldan E., Malagoli A., La Grutta S., Correra A., Notarangelo L. D. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997 Feb 1;89(3):902–909. [PubMed] [Google Scholar]
  5. Brunner T., Mogil R. J., LaFace D., Yoo N. J., Mahboubi A., Echeverri F., Martin S. J., Force W. R., Lynch D. H., Ware C. F. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 1995 Feb 2;373(6513):441–444. doi: 10.1038/373441a0. [DOI] [PubMed] [Google Scholar]
  6. Cascino I., Fiucci G., Papoff G., Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995 Mar 15;154(6):2706–2713. [PubMed] [Google Scholar]
  7. Cheng J., Liu C., Koopman W. J., Mountz J. D. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol. 1995 Feb 1;154(3):1239–1245. [PubMed] [Google Scholar]
  8. Danis V. A., Millington M., Hyland V. J., Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995 Feb;99(2):303–310. doi: 10.1111/j.1365-2249.1995.tb05549.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Danis V. A., Millington M., Hyland V., Lawford R., Huang Q., Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers. 1995 Mar;12(2):127–133. doi: 10.1155/1994/756247. [DOI] [PubMed] [Google Scholar]
  10. Davidson W. F., Dumont F. J., Bedigian H. G., Fowlkes B. J., Morse H. C., 3rd Phenotypic, functional, and molecular genetic comparisons of the abnormal lymphoid cells of C3H-lpr/lpr and C3H-gld/gld mice. J Immunol. 1986 Jun 1;136(11):4075–4084. [PubMed] [Google Scholar]
  11. Davignon J. L., Budd R. C., Ceredig R., Piguet P. F., MacDonald H. R., Cerottini J. C., Vassalli P., Izui S. Functional analysis of T cell subsets from mice bearing the lpr gene. J Immunol. 1985 Oct;135(4):2423–2428. [PubMed] [Google Scholar]
  12. Dhein J., Walczak H., Bäumler C., Debatin K. M., Krammer P. H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature. 1995 Feb 2;373(6513):438–441. doi: 10.1038/373438a0. [DOI] [PubMed] [Google Scholar]
  13. Drappa J., Vaishnaw A. K., Sullivan K. E., Chu J. L., Elkon K. B. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996 Nov 28;335(22):1643–1649. doi: 10.1056/NEJM199611283352204. [DOI] [PubMed] [Google Scholar]
  14. Fisher G. H., Rosenberg F. J., Straus S. E., Dale J. K., Middleton L. A., Lin A. Y., Strober W., Lenardo M. J., Puck J. M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995 Jun 16;81(6):935–946. doi: 10.1016/0092-8674(95)90013-6. [DOI] [PubMed] [Google Scholar]
  15. Fiucci G., Ruberti G. Detection of polymorphisms within the Fas cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis. Immunogenetics. 1994;39(6):437–439. doi: 10.1007/BF00176163. [DOI] [PubMed] [Google Scholar]
  16. Galbraith G. M., Pandey J. P. Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata. Hum Genet. 1995 Oct;96(4):433–436. doi: 10.1007/BF00191802. [DOI] [PubMed] [Google Scholar]
  17. Huang B., Eberstadt M., Olejniczak E. T., Meadows R. P., Fesik S. W. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature. 1996 Dec 19;384(6610):638–641. doi: 10.1038/384638a0. [DOI] [PubMed] [Google Scholar]
  18. Inazawa J., Itoh N., Abe T., Nagata S. Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics. 1992 Nov;14(3):821–822. doi: 10.1016/s0888-7543(05)80200-9. [DOI] [PubMed] [Google Scholar]
  19. Infante A. J., Britton H. A., DeNapoli T., Middelton L. A., Lenardo M. J., Jackson C. E., Wang J., Fleisher T., Straus S. E., Puck J. M. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J Pediatr. 1998 Nov;133(5):629–633. doi: 10.1016/s0022-3476(98)70102-7. [DOI] [PubMed] [Google Scholar]
  20. Ito M., Oiso Y., Murase T., Kondo K., Saito H., Chinzei T., Racchi M., Lively M. O. Possible involvement of inefficient cleavage of preprovasopressin by signal peptidase as a cause for familial central diabetes insipidus. J Clin Invest. 1993 Jun;91(6):2565–2571. doi: 10.1172/JCI116494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Izui S., Kelley V. E., Masuda K., Yoshida H., Roths J. B., Murphy E. D. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol. 1984 Jul;133(1):227–233. [PubMed] [Google Scholar]
  22. Ju S. T., Panka D. J., Cui H., Ettinger R., el-Khatib M., Sherr D. H., Stanger B. Z., Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995 Feb 2;373(6513):444–448. doi: 10.1038/373444a0. [DOI] [PubMed] [Google Scholar]
  23. Kasahara Y., Wada T., Niida Y., Yachie A., Seki H., Ishida Y., Sakai T., Koizumi F., Koizumi S., Miyawaki T. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int Immunol. 1998 Feb;10(2):195–202. doi: 10.1093/intimm/10.2.195. [DOI] [PubMed] [Google Scholar]
  24. Kimura M., Matsuzawa A. Autoimmunity in mice bearing lprcg: a novel mutant gene. Int Rev Immunol. 1994;11(3):193–210. doi: 10.3109/08830189409061727. [DOI] [PubMed] [Google Scholar]
  25. Landowski T. H., Qu N., Buyuksal I., Painter J. S., Dalton W. S. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997 Dec 1;90(11):4266–4270. [PubMed] [Google Scholar]
  26. Lenardo M. J. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991 Oct 31;353(6347):858–861. doi: 10.1038/353858a0. [DOI] [PubMed] [Google Scholar]
  27. Liu C., Cheng J., Mountz J. D. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochem J. 1995 Sep 15;310(Pt 3):957–963. doi: 10.1042/bj3100957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Messer G., Kick G., Ranki A., Koskimies S., Reunala T., Meurer M. Polymorphism of the tumor necrosis factor genes in patients with dermatitis herpetiformis. Dermatology. 1994;189 (Suppl 1):135–137. doi: 10.1159/000246957. [DOI] [PubMed] [Google Scholar]
  29. Nagata S. Apoptosis by death factor. Cell. 1997 Feb 7;88(3):355–365. doi: 10.1016/s0092-8674(00)81874-7. [DOI] [PubMed] [Google Scholar]
  30. Ogata Y., Kimura M., Shimada K., Wakabayashi T., Onoda H., Katagiri T., Matsuzawa A. Distinctive expression of lprcg in the heterozygous state on different genetic backgrounds. Cell Immunol. 1993 Apr 15;148(1):91–102. doi: 10.1006/cimm.1993.1093. [DOI] [PubMed] [Google Scholar]
  31. Papoff G., Cascino I., Eramo A., Starace G., Lynch D. H., Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol. 1996 Jun 15;156(12):4622–4630. [PubMed] [Google Scholar]
  32. Pensati L., Costanzo A., Ianni A., Accapezzato D., Iorio R., Natoli G., Nisini R., Almerighi C., Balsano C., Vajro P. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology. 1997 Oct;113(4):1384–1389. doi: 10.1053/gast.1997.v113.pm9322534. [DOI] [PubMed] [Google Scholar]
  33. Puck J. M., Pepper A. E., Henthorn P. S., Candotti F., Isakov J., Whitwam T., Conley M. E., Fischer R. E., Rosenblatt H. M., Small T. N. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood. 1997 Mar 15;89(6):1968–1977. [PubMed] [Google Scholar]
  34. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I. A., Debatin K. M., Fischer A., de Villartay J. P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995 Jun 2;268(5215):1347–1349. doi: 10.1126/science.7539157. [DOI] [PubMed] [Google Scholar]
  35. Sarkar G., Yoon H. S., Sommer S. S. Dideoxy fingerprinting (ddE): a rapid and efficient screen for the presence of mutations. Genomics. 1992 Jun;13(2):441–443. doi: 10.1016/0888-7543(92)90266-u. [DOI] [PubMed] [Google Scholar]
  36. Singh A., Ni J., Aggarwal B. B. Death domain receptors and their role in cell demise. J Interferon Cytokine Res. 1998 Jul;18(7):439–450. doi: 10.1089/jir.1998.18.439. [DOI] [PubMed] [Google Scholar]
  37. Sneller M. C., Straus S. E., Jaffe E. S., Jaffe J. S., Fleisher T. A., Stetler-Stevenson M., Strober W. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992 Aug;90(2):334–341. doi: 10.1172/JCI115867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sneller M. C., Wang J., Dale J. K., Strober W., Middelton L. A., Choi Y., Fleisher T. A., Lim M. S., Jaffe E. S., Puck J. M. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997 Feb 15;89(4):1341–1348. [PubMed] [Google Scholar]
  39. Sullivan K. E., Wooten C., Schmeckpeper B. J., Goldman D., Petri M. A. A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum. 1997 Dec;40(12):2207–2211. doi: 10.1002/art.1780401215. [DOI] [PubMed] [Google Scholar]
  40. Takahashi T., Tanaka M., Brannan C. I., Jenkins N. A., Copeland N. G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994 Mar 25;76(6):969–976. doi: 10.1016/0092-8674(94)90375-1. [DOI] [PubMed] [Google Scholar]
  41. Watanabe-Fukunaga R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992 Mar 26;356(6367):314–317. doi: 10.1038/356314a0. [DOI] [PubMed] [Google Scholar]
  42. Watzke H. H., Wallmark A., Hamaguchi N., Giardina P., Stafford D. W., High K. A. Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest. 1991 Nov;88(5):1685–1689. doi: 10.1172/JCI115484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wilson A. G., Gordon C., di Giovine F. S., de Vries N., van de Putte L. B., Emery P., Duff G. W. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol. 1994 Jan;24(1):191–195. doi: 10.1002/eji.1830240130. [DOI] [PubMed] [Google Scholar]
  44. Yanagawa T., DeGroot L. J. HLA class II associations in African-American female patients with Graves' disease. Thyroid. 1996 Feb;6(1):37–39. doi: 10.1089/thy.1996.6.37. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES